Investigational Drug Information for Elafibranor
✉ Email this page to a colleague
What is the development status for investigational drug Elafibranor?
Elafibranor is an investigational drug.
There have been 12 clinical trials for Elafibranor.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2016.
The most common disease conditions in clinical trials are Cholangitis, Non-alcoholic Fatty Liver Disease, and Fatty Liver. The leading clinical trial sponsors are Genfit, Ipsen, and Syneos Health.
There are fifty-two US patents protecting this investigational drug and five hundred and seventeen international patents.
Summary for Elafibranor
| US Patents | 52 |
| International Patents | 517 |
| US Patent Applications | 261 |
| WIPO Patent Applications | 272 |
| Japanese Patent Applications | 34 |
| Clinical Trial Progress | Phase 2 (2016-03-01) |
| Vendors | 55 |
Recent Clinical Trials for Elafibranor
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. | Ipsen | Phase 2 |
| A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants After Intake of a Single Tablet | Ipsen | Phase 1 |
| Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants | Ipsen | Phase 1 |
Clinical Trial Summary for Elafibranor
Top disease conditions for Elafibranor
Top clinical trial sponsors for Elafibranor
US Patents for Elafibranor
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Elafibranor | ⤷ Try a Trial | Soluble guanylate cyclase stimulators | Merck Sharp & Dohme Corp. (Rahway, NJ) | ⤷ Try a Trial |
| Elafibranor | ⤷ Try a Trial | Antidiabetic compounds | Merck Sharp & Dohme Corp. (Rahway, NJ) | ⤷ Try a Trial |
| Elafibranor | ⤷ Try a Trial | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | Bristol-Myers Squibb Company (Princeton, NJ) Syngene International Limited (Bangalore, Karnataka, IN) | ⤷ Try a Trial |
| Elafibranor | ⤷ Try a Trial | [5,6]--fused bicyclic antidiabetic compounds | Merck Sharp & Dohme Corp. (Rahway, NJ) | ⤷ Try a Trial |
| Elafibranor | ⤷ Try a Trial | [7,6]-fused bicyclic antidiabetic compounds | Merck Sharp & Dohme Corp. (Rahway, NJ) | ⤷ Try a Trial |
| Elafibranor | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Elafibranor
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Elafibranor | Argentina | AR107154 | 2035-12-22 | ⤷ Try a Trial |
| Elafibranor | Australia | AU2016377364 | 2035-12-22 | ⤷ Try a Trial |
| Elafibranor | Brazil | BR112018012579 | 2035-12-22 | ⤷ Try a Trial |
| Elafibranor | Canada | CA3009193 | 2035-12-22 | ⤷ Try a Trial |
| Elafibranor | Chile | CL2018001671 | 2035-12-22 | ⤷ Try a Trial |
| Elafibranor | China | CN108738320 | 2035-12-22 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
